Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | 2018
The treatment landscape for NSCLC continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies into new patient populations. Examples include the approvals of Alunbrig for ALK-positive metastatic NSCLC,Tafinlar plus Mekinist for BRAF-mutation-positive NSCLC, and Imfinzi for unresectable stage III NSCLC as well as the label expansion of Keytruda in combination with chemotherapy as a first-line regimen for metastatic nonsquamous patients. Our primary research provides insight into the current use of approved therapies for NSCLC in the United States and uncovers key factors that influence medical oncologists’ prescribing decisions in this highly dynamic indication.
Related Market Assessment Reports
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Bipolar Disorder – Current Treatment – Current Treatment: Physician Insights – Bipolar Disorder (EU5)
Bipolar disorder (BD) is a spectrum disorder characterized by recurrent episodes of aberrant mood; patients may exhibit manic, depressive, or mixed symptoms between periods of stable mood. Lithium…
